<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10415172</article-id>
    <article-id pub-id-type="pmid">37549060</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad489</article-id>
    <article-id pub-id-type="publisher-id">btad489</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PACT: a pipeline for analysis of circulating tumor DNA</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Webster</surname>
          <given-names>Jace</given-names>
        </name>
        <aff><institution>McDonnell Genome Institute, Washington University in St. Louis</institution>, MO 63108, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dang</surname>
          <given-names>Ha X</given-names>
        </name>
        <aff><institution>McDonnell Genome Institute, Washington University in St. Louis</institution>, MO 63108, <country country="US">United States</country></aff>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chauhan</surname>
          <given-names>Pradeep S</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6320-3927</contrib-id>
        <name>
          <surname>Feng</surname>
          <given-names>Wenjia</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shiang</surname>
          <given-names>Alex</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Harris</surname>
          <given-names>Peter K</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pachynski</surname>
          <given-names>Russell K</given-names>
        </name>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <xref rid="btad489-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chaudhuri</surname>
          <given-names>Aadel A</given-names>
        </name>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Genetics, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Biomedical Engineering, Washington University in St. Louis</institution>, MO 63130, <country country="US">United States</country></aff>
        <aff><institution>Department of Computer Science and Engineering, Washington University in St. Louis</institution>, MO 63130, <country country="US">United States</country></aff>
        <xref rid="btad489-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9035-603X</contrib-id>
        <name>
          <surname>Maher</surname>
          <given-names>Christopher A</given-names>
        </name>
        <aff><institution>McDonnell Genome Institute, Washington University in St. Louis</institution>, MO 63108, <country country="US">United States</country></aff>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Biomedical Engineering, Washington University in St. Louis</institution>, MO 63130, <country country="US">United States</country></aff>
        <xref rid="btad489-FM1" ref-type="author-notes"/>
        <xref rid="btad489-cor1" ref-type="corresp"/>
        <!--Christophermaher@wustl.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Birol</surname>
          <given-names>Inanc</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad489-cor1">Corresponding author. McDonnell Genome Institute, Washington University in St. Louis, MO 63108, United States. E-mail: <email>Christophermaher@wustl.edu</email> (C.A.M.)</corresp>
      <fn id="btad489-FM1">
        <p>Russell K Pachynski and Aadel A Chaudhuri contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-08-07">
      <day>07</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>07</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>8</issue>
    <elocation-id>btad489</elocation-id>
    <history>
      <date date-type="received">
        <day>18</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>26</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>31</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>04</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>10</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad489.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Detection of genomic alterations in circulating tumor DNA (ctDNA) is currently used for active clinical monitoring of cancer progression and treatment response. While methods for analysis of small mutations are more developed, strategies for detecting structural variants (SVs) in ctDNA are limited. Additionally, reproducibly calling small-scale mutations, copy number alterations, and SVs in ctDNA is challenging due to the lack to unified tools for these different classes of variants.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We developed a unified pipeline for the analysis of ctDNA [<underline>P</underline>ipeline for the <underline>A</underline>nalysis of <underline>ct</underline>DNA (PACT)] that accurately detects SVs and consistently outperformed similar tools when applied to simulated, cell line, and clinical data. We provide PACT in the form of a Common Workflow Language pipeline which can be run by popular workflow management systems in high-performance computing environments.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>PACT is freely available at <ext-link xlink:href="https://github.com/ChrisMaherLab/PACT" ext-link-type="uri">https://github.com/ChrisMaherLab/PACT</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Identification of genomic variants in circulating tumor DNA (ctDNA) has emerged as a promising method for non-invasive monitoring of cancer progression and treatment response. This non-invasive monitoring is particularly beneficial in metastatic disease as ctDNA originating from both primary and secondary tumor sites can be found within a single blood sample. Despite low ctDNA abundance and expected allele frequencies, deep targeted sequencing has been successfully used to improve sensitivity (<xref rid="btad489-B1" ref-type="bibr">Corcoran and Chabner 2018</xref>) for detecting single-nucleotide variants (SNVs). Structural variants (SVs) are a major class of genomic drivers of cancer progression (<xref rid="btad489-B2" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020a</xref>) but their use in non-invasive applications remains limited due to the challenges of accurately detecting the wide variety of possible complex genomic rearrangements.</p>
    <p>When attempting to overcome the limitations of current ctDNA SV callers, while also identifying copy number alterations (CNAs) and small mutations, users often resort to <italic toggle="yes">ad hoc</italic> or proprietary approaches. This leads to time-consuming analyses and inhibits reproducibility in the field, in part because of the variety of possible customizable tools and parameters required. A few tools have been developed for SV detection in ctDNA; however, each of the identified tools has crucial limitations inhibiting their ability to identify clinically relevant events (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). For example, none of them accept matched germline control data, which is critical for differentiating artifacts, germline, and somatic events.</p>
    <p>To address these limitations and promote the accurate and reproducible detection of SVs, CNAs, and small mutations in ctDNA, we developed an open-source unified <underline>P</underline>ipeline for the <underline>A</underline>nalysis of <underline>ct</underline>DNA (PACT).</p>
  </sec>
  <sec>
    <title>2 Methods</title>
    <p>PACT is a standardized ctDNA pipeline for detection of SVs, CNAs, and small mutations. It is designed for reproducibility in high-performance computing environments capable of processing large numbers of samples and can be run by popular workflow management systems.</p>
    <p>PACT consists of methods for detection of small mutations, CNAs, and SVs independently (<xref rid="btad489-F1" ref-type="fig">Fig. 1A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>; expanded in <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). Briefly, each variant calling strategy begins with the creation of an initial list of candidates nominated using an ensemble of tools for variant calling. Where possible, each tool is run using relaxed filtering criteria to increase sensitivity (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). To obtain high specificity, normalization and/or filtering strategies are applied to all nominated variants based on expected noise in ctDNA caused in part by deep sequencing and low allele frequencies (often &lt;1%) (<xref rid="btad489-B1" ref-type="bibr">Corcoran and Chabner 2018</xref>). All workflows accept sequencing data from matched controls and from a panel of unmatched, healthy individuals to aid in removing non-somatic events.</p>
    <fig position="float" id="btad489-F1">
      <label>Figure 1.</label>
      <caption>
        <p>Summary of PACT workflow and benchmarking. (A) Overview of PACT workflow. (B) <italic toggle="yes">In silico</italic> and (C) <italic toggle="yes">in vitro</italic> benchmarking summaries.</p>
      </caption>
      <graphic xlink:href="btad489f1" position="float"/>
    </fig>
    <p>For SVs, consensus calls are first genotyped against both matched and unmatched controls to remove artifactual calls and germline events. After comparisons to controls are made, regional filters require at least one breakpoint of an SV to originate in a region targeted by the sequencing panel to ensure relevance and correct mapping, while removing calls from genomic regions with known high false positive rates. Finally, multiple forms of evidence (split-read and discordant paired-end read) are required for final SV nomination.</p>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>Although SNV and CNA strategies for ctDNA are usually considered robust, SV detection has traditionally been challenging. While PACT integrates callers of various variant types, its major focus is on improving SV analysis in ctDNA. Here, we benchmark our tool using (i) patient data, (ii) an <italic toggle="yes">in silico</italic> simulation, and (iii) a dilution experiment, while comparing against other ctDNA SV callers including SViCT, Factera, and Aperture (<xref rid="btad489-B6" ref-type="bibr">Newman <italic toggle="yes">et al.</italic> 2014</xref>, <xref rid="btad489-B4" ref-type="bibr">Gawroński <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad489-B5" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> 2021</xref>).</p>
    <p>First, we applied each tool to ctDNA samples from a published cohort of 40 prostate cancer patients and found that only PACT and Aperture detected all published SVs (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>) (<xref rid="btad489-B2" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020a</xref>). Precision was not assessed due to the lack of gold standard positive controls. Similarly, only PACT and Aperture identified all expected SVs in a public cfDNA reference dataset (SRA: SRR8551545). However, Aperture reported 1636 unvalidated SVs in the reference data (1623 more than the next highest tool, Factera), suggesting poor precision (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S3</xref>).</p>
    <p>Second, we performed an <italic toggle="yes">in silico</italic> simulation with tumor data from four prostate (<xref rid="btad489-B2" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020a</xref>) and five colorectal (<xref rid="btad489-B3" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020b</xref>) cancer patients (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). Sequencing reads from tumor and respective matched controls were combined to simulate ctDNA content ranging from 0.1% to 30%, bounded by the tumor purity of original samples. At each dilution, PACT achieved the highest sensitivity (<xref rid="btad489-F1" ref-type="fig">Fig. 1B</xref>). Specificity was not assessed as validation of novel calls could not be performed; however, we observed that Aperture and Factera consistently had the most candidates (i.e. approximately 13× and 8× more than PACT at 7.5% tumor DNA content; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S4</xref>), suggesting potentially poor precision.</p>
    <p>Our third evaluation was performed using an <italic toggle="yes">in vitro</italic> dilution experiment of the well characterized breast cancer cell line (HCC1395) and its matched control cell line (HCC1395BL). We mixed these cells to create diluted samples with 0.1%–100% tumor content. Targeted sequencing of 26 validated SVs was then performed. We found that PACT achieved the highest sensitivity and F1 accuracy scores and was the only tool to achieve &gt;90% sensitivity at all dilutions &gt;3% (<xref rid="btad489-F1" ref-type="fig">Fig. 1C</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref>). At the lowest detectable level (0.12% tumor content), PACT, Aperture, and Factera achieved 15%, 10%, and 0% sensitivity, respectively.</p>
    <p>Together, these results suggest that PACT is both more sensitive and more precise than other ctDNA SV callers. By including SNV and CNA workflows within PACT and distributing the pipeline in a standardized workflow language, PACT is well suited for improving accuracy and reproducibility in ctDNA analysis, with potential clinical applications.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad489_Supplementary_Data</label>
      <media xlink:href="btad489_supplementary_data.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>R.K.P.: Advisory Role: EMD Serono, Bristol Myers Squibb, Pfizer/EMD Serono, Sanofi, Jounce Therapeutics, Dendreon, Bayer, Genomic Health. Speakers’ Bureau: Dendreon, Merck, Genentech/Roche, AstraZeneca, Sanofi, Genomic Health. Intellectual Property: Tempus. A.A.C.: Stock/Ownership Interests: Geneoscopy, Droplet Biosciences, and LiquidCell DX. Advisory Role: Foundation Medicine, Geneoscopy, Roche, Fenix Group Internal, Tempus, Illumina, Invitae, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio, and Guidepoint. Intellectual Property: Patents related to cancer biomarkers and has licensed technology to Droplet Biosciences, Tempus Labs, LiquidCell Dx and Biocognitive Labs. Received honoraria from Agilent, Roche, and Dava Oncology. C.A.M.: Intellectual Property: Tempus. No other potential conflicts were reported.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Alvin J. Siteman Cancer Research Fund at Washington University in St. Louis (A.A.C., C.A.M., R.K.P.), the National Cancer Institute of the National Institutes of Health under award number K08CA238711 (A.A.C.), the Cancer Research Foundation Young Investigator Award (A.A.C.), the American Cancer Society Institutional Research Grant: IRG-18-158-61 (H.X.D.), the Prostate Cancer Foundation Young Investigator Award (R.K.P.), the Sidney Kimmel Scholar Award (R.K.P.), the Galen Hoskin and Dina Wolkoff Giving Fund (R.K.P.), and the National Institutes of Health Clinical Center: 1 F31 CA265010-01 (J.W.).</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad489-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corcoran</surname><given-names>RB</given-names></string-name>, <string-name><surname>Chabner</surname><given-names>BA.</given-names></string-name></person-group>  <article-title>Application of cell-free DNA analysis to cancer treatment</article-title>. <source>N Engl J Med</source>  <year>2018</year>;<volume>379</volume>:<fpage>1754</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">30380390</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dang</surname><given-names>HX</given-names></string-name>, <string-name><surname>Chauhan</surname><given-names>PS</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>H</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer</article-title>. <source>JCO Precis Oncol</source>  <year>2020a</year>;<volume>4</volume>:<fpage>680</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">32903952</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dang</surname><given-names>HX</given-names></string-name>, <string-name><surname>Krasnick</surname><given-names>BA</given-names></string-name>, <string-name><surname>White</surname><given-names>BS</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>The clonal evolution of metastatic colorectal cancer</article-title>. <source>Sci Adv</source>  <year>2020b</year>;<volume>6</volume>:<fpage>eaay9691</fpage>.<pub-id pub-id-type="pmid">32577507</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gawroński</surname><given-names>AR</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y-Y</given-names></string-name>, <string-name><surname>McConeghy</surname><given-names>B</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA</article-title>. <source>Nucleic Acids Res</source>  <year>2019</year>;<volume>47</volume>:<fpage>e38</fpage>.<pub-id pub-id-type="pmid">30759232</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>Aperture: alignment-free detection of structural variations and viral integrations in circulating tumor DNA</article-title>. <source>Brief Bioinform</source>  <year>2021</year>;<volume>22</volume>:<fpage>bbab290</fpage>.<pub-id pub-id-type="pmid">34368852</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Newman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Bratman</surname><given-names>SV</given-names></string-name>, <string-name><surname>Stehr</surname><given-names>H</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution</article-title>. <source>Bioinformatics</source>  <year>2014</year>;<volume>30</volume>:<fpage>3390</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">25143292</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10415172</article-id>
    <article-id pub-id-type="pmid">37549060</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad489</article-id>
    <article-id pub-id-type="publisher-id">btad489</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PACT: a pipeline for analysis of circulating tumor DNA</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Webster</surname>
          <given-names>Jace</given-names>
        </name>
        <aff><institution>McDonnell Genome Institute, Washington University in St. Louis</institution>, MO 63108, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dang</surname>
          <given-names>Ha X</given-names>
        </name>
        <aff><institution>McDonnell Genome Institute, Washington University in St. Louis</institution>, MO 63108, <country country="US">United States</country></aff>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chauhan</surname>
          <given-names>Pradeep S</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6320-3927</contrib-id>
        <name>
          <surname>Feng</surname>
          <given-names>Wenjia</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shiang</surname>
          <given-names>Alex</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Harris</surname>
          <given-names>Peter K</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pachynski</surname>
          <given-names>Russell K</given-names>
        </name>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <xref rid="btad489-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chaudhuri</surname>
          <given-names>Aadel A</given-names>
        </name>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Radiation Oncology, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Genetics, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Biomedical Engineering, Washington University in St. Louis</institution>, MO 63130, <country country="US">United States</country></aff>
        <aff><institution>Department of Computer Science and Engineering, Washington University in St. Louis</institution>, MO 63130, <country country="US">United States</country></aff>
        <xref rid="btad489-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9035-603X</contrib-id>
        <name>
          <surname>Maher</surname>
          <given-names>Christopher A</given-names>
        </name>
        <aff><institution>McDonnell Genome Institute, Washington University in St. Louis</institution>, MO 63108, <country country="US">United States</country></aff>
        <aff><institution>Siteman Cancer Center, Washington University in St. Louis</institution>, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Medicine, Washington University School of Medicine</institution>, St. Louis, MO 63110, <country country="US">United States</country></aff>
        <aff><institution>Department of Biomedical Engineering, Washington University in St. Louis</institution>, MO 63130, <country country="US">United States</country></aff>
        <xref rid="btad489-FM1" ref-type="author-notes"/>
        <xref rid="btad489-cor1" ref-type="corresp"/>
        <!--Christophermaher@wustl.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Birol</surname>
          <given-names>Inanc</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad489-cor1">Corresponding author. McDonnell Genome Institute, Washington University in St. Louis, MO 63108, United States. E-mail: <email>Christophermaher@wustl.edu</email> (C.A.M.)</corresp>
      <fn id="btad489-FM1">
        <p>Russell K Pachynski and Aadel A Chaudhuri contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-08-07">
      <day>07</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>07</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>8</issue>
    <elocation-id>btad489</elocation-id>
    <history>
      <date date-type="received">
        <day>18</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>26</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>31</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>04</day>
        <month>8</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>10</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad489.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Detection of genomic alterations in circulating tumor DNA (ctDNA) is currently used for active clinical monitoring of cancer progression and treatment response. While methods for analysis of small mutations are more developed, strategies for detecting structural variants (SVs) in ctDNA are limited. Additionally, reproducibly calling small-scale mutations, copy number alterations, and SVs in ctDNA is challenging due to the lack to unified tools for these different classes of variants.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We developed a unified pipeline for the analysis of ctDNA [<underline>P</underline>ipeline for the <underline>A</underline>nalysis of <underline>ct</underline>DNA (PACT)] that accurately detects SVs and consistently outperformed similar tools when applied to simulated, cell line, and clinical data. We provide PACT in the form of a Common Workflow Language pipeline which can be run by popular workflow management systems in high-performance computing environments.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>PACT is freely available at <ext-link xlink:href="https://github.com/ChrisMaherLab/PACT" ext-link-type="uri">https://github.com/ChrisMaherLab/PACT</ext-link>.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Identification of genomic variants in circulating tumor DNA (ctDNA) has emerged as a promising method for non-invasive monitoring of cancer progression and treatment response. This non-invasive monitoring is particularly beneficial in metastatic disease as ctDNA originating from both primary and secondary tumor sites can be found within a single blood sample. Despite low ctDNA abundance and expected allele frequencies, deep targeted sequencing has been successfully used to improve sensitivity (<xref rid="btad489-B1" ref-type="bibr">Corcoran and Chabner 2018</xref>) for detecting single-nucleotide variants (SNVs). Structural variants (SVs) are a major class of genomic drivers of cancer progression (<xref rid="btad489-B2" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020a</xref>) but their use in non-invasive applications remains limited due to the challenges of accurately detecting the wide variety of possible complex genomic rearrangements.</p>
    <p>When attempting to overcome the limitations of current ctDNA SV callers, while also identifying copy number alterations (CNAs) and small mutations, users often resort to <italic toggle="yes">ad hoc</italic> or proprietary approaches. This leads to time-consuming analyses and inhibits reproducibility in the field, in part because of the variety of possible customizable tools and parameters required. A few tools have been developed for SV detection in ctDNA; however, each of the identified tools has crucial limitations inhibiting their ability to identify clinically relevant events (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). For example, none of them accept matched germline control data, which is critical for differentiating artifacts, germline, and somatic events.</p>
    <p>To address these limitations and promote the accurate and reproducible detection of SVs, CNAs, and small mutations in ctDNA, we developed an open-source unified <underline>P</underline>ipeline for the <underline>A</underline>nalysis of <underline>ct</underline>DNA (PACT).</p>
  </sec>
  <sec>
    <title>2 Methods</title>
    <p>PACT is a standardized ctDNA pipeline for detection of SVs, CNAs, and small mutations. It is designed for reproducibility in high-performance computing environments capable of processing large numbers of samples and can be run by popular workflow management systems.</p>
    <p>PACT consists of methods for detection of small mutations, CNAs, and SVs independently (<xref rid="btad489-F1" ref-type="fig">Fig. 1A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>; expanded in <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). Briefly, each variant calling strategy begins with the creation of an initial list of candidates nominated using an ensemble of tools for variant calling. Where possible, each tool is run using relaxed filtering criteria to increase sensitivity (<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>). To obtain high specificity, normalization and/or filtering strategies are applied to all nominated variants based on expected noise in ctDNA caused in part by deep sequencing and low allele frequencies (often &lt;1%) (<xref rid="btad489-B1" ref-type="bibr">Corcoran and Chabner 2018</xref>). All workflows accept sequencing data from matched controls and from a panel of unmatched, healthy individuals to aid in removing non-somatic events.</p>
    <fig position="float" id="btad489-F1">
      <label>Figure 1.</label>
      <caption>
        <p>Summary of PACT workflow and benchmarking. (A) Overview of PACT workflow. (B) <italic toggle="yes">In silico</italic> and (C) <italic toggle="yes">in vitro</italic> benchmarking summaries.</p>
      </caption>
      <graphic xlink:href="btad489f1" position="float"/>
    </fig>
    <p>For SVs, consensus calls are first genotyped against both matched and unmatched controls to remove artifactual calls and germline events. After comparisons to controls are made, regional filters require at least one breakpoint of an SV to originate in a region targeted by the sequencing panel to ensure relevance and correct mapping, while removing calls from genomic regions with known high false positive rates. Finally, multiple forms of evidence (split-read and discordant paired-end read) are required for final SV nomination.</p>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>Although SNV and CNA strategies for ctDNA are usually considered robust, SV detection has traditionally been challenging. While PACT integrates callers of various variant types, its major focus is on improving SV analysis in ctDNA. Here, we benchmark our tool using (i) patient data, (ii) an <italic toggle="yes">in silico</italic> simulation, and (iii) a dilution experiment, while comparing against other ctDNA SV callers including SViCT, Factera, and Aperture (<xref rid="btad489-B6" ref-type="bibr">Newman <italic toggle="yes">et al.</italic> 2014</xref>, <xref rid="btad489-B4" ref-type="bibr">Gawroński <italic toggle="yes">et al.</italic> 2019</xref>, <xref rid="btad489-B5" ref-type="bibr">Liu <italic toggle="yes">et al.</italic> 2021</xref>).</p>
    <p>First, we applied each tool to ctDNA samples from a published cohort of 40 prostate cancer patients and found that only PACT and Aperture detected all published SVs (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>) (<xref rid="btad489-B2" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020a</xref>). Precision was not assessed due to the lack of gold standard positive controls. Similarly, only PACT and Aperture identified all expected SVs in a public cfDNA reference dataset (SRA: SRR8551545). However, Aperture reported 1636 unvalidated SVs in the reference data (1623 more than the next highest tool, Factera), suggesting poor precision (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S3</xref>).</p>
    <p>Second, we performed an <italic toggle="yes">in silico</italic> simulation with tumor data from four prostate (<xref rid="btad489-B2" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020a</xref>) and five colorectal (<xref rid="btad489-B3" ref-type="bibr">Dang <italic toggle="yes">et al.</italic> 2020b</xref>) cancer patients (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). Sequencing reads from tumor and respective matched controls were combined to simulate ctDNA content ranging from 0.1% to 30%, bounded by the tumor purity of original samples. At each dilution, PACT achieved the highest sensitivity (<xref rid="btad489-F1" ref-type="fig">Fig. 1B</xref>). Specificity was not assessed as validation of novel calls could not be performed; however, we observed that Aperture and Factera consistently had the most candidates (i.e. approximately 13× and 8× more than PACT at 7.5% tumor DNA content; <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S4</xref>), suggesting potentially poor precision.</p>
    <p>Our third evaluation was performed using an <italic toggle="yes">in vitro</italic> dilution experiment of the well characterized breast cancer cell line (HCC1395) and its matched control cell line (HCC1395BL). We mixed these cells to create diluted samples with 0.1%–100% tumor content. Targeted sequencing of 26 validated SVs was then performed. We found that PACT achieved the highest sensitivity and F1 accuracy scores and was the only tool to achieve &gt;90% sensitivity at all dilutions &gt;3% (<xref rid="btad489-F1" ref-type="fig">Fig. 1C</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref>). At the lowest detectable level (0.12% tumor content), PACT, Aperture, and Factera achieved 15%, 10%, and 0% sensitivity, respectively.</p>
    <p>Together, these results suggest that PACT is both more sensitive and more precise than other ctDNA SV callers. By including SNV and CNA workflows within PACT and distributing the pipeline in a standardized workflow language, PACT is well suited for improving accuracy and reproducibility in ctDNA analysis, with potential clinical applications.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad489_Supplementary_Data</label>
      <media xlink:href="btad489_supplementary_data.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>R.K.P.: Advisory Role: EMD Serono, Bristol Myers Squibb, Pfizer/EMD Serono, Sanofi, Jounce Therapeutics, Dendreon, Bayer, Genomic Health. Speakers’ Bureau: Dendreon, Merck, Genentech/Roche, AstraZeneca, Sanofi, Genomic Health. Intellectual Property: Tempus. A.A.C.: Stock/Ownership Interests: Geneoscopy, Droplet Biosciences, and LiquidCell DX. Advisory Role: Foundation Medicine, Geneoscopy, Roche, Fenix Group Internal, Tempus, Illumina, Invitae, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio, and Guidepoint. Intellectual Property: Patents related to cancer biomarkers and has licensed technology to Droplet Biosciences, Tempus Labs, LiquidCell Dx and Biocognitive Labs. Received honoraria from Agilent, Roche, and Dava Oncology. C.A.M.: Intellectual Property: Tempus. No other potential conflicts were reported.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported by the Alvin J. Siteman Cancer Research Fund at Washington University in St. Louis (A.A.C., C.A.M., R.K.P.), the National Cancer Institute of the National Institutes of Health under award number K08CA238711 (A.A.C.), the Cancer Research Foundation Young Investigator Award (A.A.C.), the American Cancer Society Institutional Research Grant: IRG-18-158-61 (H.X.D.), the Prostate Cancer Foundation Young Investigator Award (R.K.P.), the Sidney Kimmel Scholar Award (R.K.P.), the Galen Hoskin and Dina Wolkoff Giving Fund (R.K.P.), and the National Institutes of Health Clinical Center: 1 F31 CA265010-01 (J.W.).</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad489-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corcoran</surname><given-names>RB</given-names></string-name>, <string-name><surname>Chabner</surname><given-names>BA.</given-names></string-name></person-group>  <article-title>Application of cell-free DNA analysis to cancer treatment</article-title>. <source>N Engl J Med</source>  <year>2018</year>;<volume>379</volume>:<fpage>1754</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">30380390</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dang</surname><given-names>HX</given-names></string-name>, <string-name><surname>Chauhan</surname><given-names>PS</given-names></string-name>, <string-name><surname>Ellis</surname><given-names>H</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer</article-title>. <source>JCO Precis Oncol</source>  <year>2020a</year>;<volume>4</volume>:<fpage>680</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">32903952</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dang</surname><given-names>HX</given-names></string-name>, <string-name><surname>Krasnick</surname><given-names>BA</given-names></string-name>, <string-name><surname>White</surname><given-names>BS</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>The clonal evolution of metastatic colorectal cancer</article-title>. <source>Sci Adv</source>  <year>2020b</year>;<volume>6</volume>:<fpage>eaay9691</fpage>.<pub-id pub-id-type="pmid">32577507</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gawroński</surname><given-names>AR</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y-Y</given-names></string-name>, <string-name><surname>McConeghy</surname><given-names>B</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA</article-title>. <source>Nucleic Acids Res</source>  <year>2019</year>;<volume>47</volume>:<fpage>e38</fpage>.<pub-id pub-id-type="pmid">30759232</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>Aperture: alignment-free detection of structural variations and viral integrations in circulating tumor DNA</article-title>. <source>Brief Bioinform</source>  <year>2021</year>;<volume>22</volume>:<fpage>bbab290</fpage>.<pub-id pub-id-type="pmid">34368852</pub-id></mixed-citation>
    </ref>
    <ref id="btad489-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Newman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Bratman</surname><given-names>SV</given-names></string-name>, <string-name><surname>Stehr</surname><given-names>H</given-names></string-name></person-group>  <etal>et al</etal>  <article-title>FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution</article-title>. <source>Bioinformatics</source>  <year>2014</year>;<volume>30</volume>:<fpage>3390</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">25143292</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
